NEW YORK, Nov. 11, 2013 /PRNewswire/ -- Bronstein, Gewirtz
& Grossman, LLC is investigating potential claims against the
Board of Directors of ViroPharma, Inc. ("ViroPharma" or the
"Company") (NasdaqGS:VPHM) related to the proposed acquisition of
the Company by Shire PLC. The transaction is valued at around
$4.2 billion or $50 per share.
This investigation concerns whether the Board of Directors of
ViroPharma breached their fiduciary duties to stockholders by
failing to adequately shop the Company before agreeing to enter
into the proposed transaction, and whether the Company has
disclosed all material information to shareholders about the
transaction.
If you are aware of any facts relating to this investigation, or
purchased shares of ViroPharma, you can assist this investigation
by contacting either Peretz
Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz &
Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those
who inquire by e-mail are encouraged to include their mailing
address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484
info@bgandg.com
SOURCE Bronstein, Gewirtz & Grossman, LLC